New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:15 EDTAMPEAmpio's Ampion shows positive results in arthritis study extension
Ampio announced results of the 20 weeks extension of the Ampion SPRING study to be presented at the Western Orthopedic Association Conference in July. This 20-week extension of a multicenter study evaluated the safety and efficacy of a single intra-articular injection of Ampion treatment of inflammation-associated pain in symptomatic OA of the knee. At 20 weeks, the percentage of patients in the moderate-to-severe subgroup who reported a reduction in pain was significantly higher for patients who received Ampion - 50% - compared to those who received vehicle control - 25% -. Similar rates and severity of adverse events were observed in the Ampion and vehicle control groups. A single injection of Ampion was associated with sustained improvements in knee pain over 20 weeks.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 22, 2015
08:31 EDTAMPEAmpio announces additional study ersults for Optina
Ampio announced that further data analysis from the 12-week multi-center, placebo-controlled, double-masked randomized trial identified a reversal of pathological changes and a synergistic effect with other medication. As previously reported, oral treatment with Optina has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal thickness in patients with diabetic macular edema when given the optimal dose. An independent specialized ophthalmology company reviewed a representative set of images of the eye from the trial and identified positive changes in Optina treated patients compared to placebo. These changes included the reversal of complications such as cystic lesions and subretinal fluid. Additionally, analysis revealed that 69% of the patients in the Optina™ Study received a standard of care medication that manages kidney-induced high blood pressure. The drugs referred to as ACE Inhibitors or ARBs are commonly prescribed to diabetic patients. When this group received the optimal Optina™ dose, they showed a six-letter improvement compared to placebo, regardless of whether or not they previously had anti-VEGF eye injections. There was a significant 34 micron reduction in central retinal thickness over placebo. 60% of these eyes showed a restoration of at least one line of vision compared to only 27% of placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use